On Sunday at 1 a.m. Eastern time, an announcement went out from the first-generation gene therapy company for Duchenne muscular dystrophy: A second patient who had been treated with Elevidys has died.

Elevidys is the first gene therapy approved in the U.S. for the rare muscle-wasting condition, but it has faced scrutiny since its accelerated approval in 2023.

The death of a second teenage boy from liver failure caused by a gene therapy from Sarepta Therapeutics has left the Duchenne muscular dystrophy community angry, fearful, and divided over whether ...

Sarepta also revealed that it was pausing dosing in one of its ELEVIDYS clinical studies. On this news, Sarepta's stock price fell $15.24 per share, or 42.12%, to close at $20.91 per share on June ...

Biotech pauses trial after second patient death linked to gene therapy Sarepta Therapeutics said it would temporarily stop shipping treatments for certain Duchenne muscular dystrophy patients.

FDA evaluating further regulatory actions after deaths Elevidys is the only gene therapy for Duchenne muscular dystrophy Sarepta suggested updating Elevidys' label June 24 (Reuters) - The U.S ...